Corrigendum: Case Series: Maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequalae of COVID (PASC)
Bruce K. Patterson, Ram Yogendra, Jose Guevara-Coto, Rodrigo A. Mora-Rodriguez, Eric Osgood, John Bream, Purvi Parikh, Mark Kreimer, Devon Jeffers, Cedric Rutland, Gary Kaplan, Michael Zgoda
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsHematological disorders and diagnostics · Inflammasome and immune disorders · COVID-19 Clinical Research Studies
In the published article there was an error in the Methodology section.
The sentence previously said:
“The records and immunological lab reports from 18 adult PASC patients treated with maraviroc 300 mg per oral twice daily and pravastatin 10 mg per oral daily from our virtual medical clinic were collected and analyzed.
The 18 participants selected for this case series were from a pool of patients who reported symptom improvement while on maraviroc and pravastatin and who fit the inclusion and exclusion criteria we set below.”
The corrected sentence appears below:
“The medical records and immunological lab reports from 18 adult PASC patients treated with maraviroc 300 mg per oral twice daily and pravastatin 10 mg per oral daily by independent private practice physicians and clinics were collected and analyzed. The CCTC is a virtual consultation group that works in collaboration with these physicians to collect and analyze immunological data. The 18 patients selected for this case series were from a pool of patients who reported symptom improvement while on maraviroc and pravastatin and who fit the inclusion and exclusion criteria we set below:
5 patients were previously treated with ivermectin, 2 with fluvoxamine, and 1 with prednisone.”
In the original manuscript there was an error in the Results section, the Y axis in Figures 2, 3 lacked metric units and the data plots were too clustered for visibility.
In Figure 2, we created absolute difference for before and after cytokine measurements for each of the 14 cytokines since the original graph was too clustered and hard to interpret. In the corrected version, we also added the y-axis legend (in pg/ml) for clarity.
In Figure 3, we added box plots and added the y-axis legend for clarity. The following revised Figures are below. We renamed the Y-axis to “Subjective Score Values” and the X-axis to “Subjective Scores.”
In the published article, there was an error in the Ethics statement. The sentence previously stated:
“The studies involving human participants were reviewed and approved by CCTC Ethics and IRB Committee. The patients/participants provided their written informed consent to participate in this study.”
The corrected sentence appears below:
Ethics statement
The studies involving human participants were reviewed and approved by the CCTC IRB committee. The CCTC IRB is financially and operationally independent of the CCTC. No one from this IRB has any financial or research stake in IncellDX or CCTC. This IRB was chosen for cost reasons as this study was self-funded with limited resources. The study protocol was approved by this IRB because it was only designed to collect and analyze patient data from independent physician practices who were responsible for prescribing and monitoring the medications. The CCTC did not and does not prescribe or monitor any medications and has been set up only as a data analytics practice.
In the published article, there was an error in the Funding statement. We did not state that there was no funding received for the study. The correct Funding statement appears below.